SEC declares Form F‑4 effective, Impact shareholders to vote on Zoar merger Nov 13
The U.S. Securities and Exchange Commission approved the Form F‑4 registration for the business combination of Impact Biomedical, DSS and Zoar Limited on October 23, 2026. Impact’s shareholders are slated to meet on November 13, 2026 at 10:00 a.m. Eastern to vote on the merger. The combined entity will be named Zoar Limited and plans to list on NYSE American under the ticker ZOAR, subject to listing approval.
Why it matters
The shareholder vote is required for the merger to close; without approval the transaction cannot proceed. Listing the new company on NYSE American would provide liquidity for the combined business and could affect the share price of DSS and IBO.
Key facts
- 1The SEC declared the Form F‑4 registration statement effective on October 23, 2026. stocktitan.net
- 2Impact Biomedical’s shareholders will meet on November 13, 2026 at 10:00 a.m. Eastern to vote on the merger. finanznachrichten.de
- 3The combined company will be called Zoar Limited and intends to trade on NYSE American under the ticker ZOAR, pending listing approval. finanznachrichten.de
- 4DSS, Inc. is the majority shareholder of Impact Biomedical. stocktitan.net
- 5Closing of the transaction remains subject to shareholder approval and NYSE American listing approval. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.